臨床整形外科46巻9号

2011年09月発行

誌上シンポジウム 生物学的製剤が与えた関節リウマチの病態・治療の変化

骨関節破壊予防と破骨細胞標的薬

著者： 門野夕峰¹ 田中栄¹

所属機関： ¹東京大学大学院医学系研究科感覚・運動機能医学整形外科

ページ範囲：P.819 - P.823

　生物学的製剤の登場により関節リウマチ治療は転換期を迎え，臨床的寛解を目標とした治療が現実のものとなっている．画像的寛解を達成するためには，関節炎を抑制するだけでなく骨関節破壊も抑制することが必要不可欠である．破骨細胞による骨吸収を抑制するビスフォスフォネート製剤は臨床応用されているが，骨組織に長期間残存するという欠点がある．他にも破骨細胞分化自体を抑制する抗RANKL抗体など実用化が間近なものから，破骨細胞機能を抑制するカテプシンK阻害薬など，破骨細胞を標的とした治療薬が開発されている．

参考文献

1) Asagiri M, Hirai T, Kunigami T, et al:Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science 319:624-627, 2008

2) Bauer DC:Discontinuation of odanacatib and other osteoporosis treatments:here today and gone tomorrow? J Bone Miner Res 26:239-241, 2011

3) Choi Y, Arron JR, Townsend MJ:Promising bone-related therapeutic targets for rheumatoid arthritis. Nat Rev Rheumatol 5:543-548, 2009

4) Cohen SB, Dore RK, Lane NE, et al:Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis:a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58:1299-1309, 2008

5) Deodhar A, Dore RK, Mandel D, et al:Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 62:569-574, 2010

6) Diarra D, Stolina M, Polzer K, et al:Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156-163, 2007

7) Hannon RA, Clack G, Rimmer M, et al:Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men:a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. J Bone Miner Res 25:463-471, 2010

8) Hashimoto J, Garnero P, van der Heijde D, et al:Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI:data from the SAMURAI study. Mod Rheumatol 21:10-15, 2011

9) Keystone EC, Kavanaugh AF, Sharp JT, et al:Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy:a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50:1400-1411, 2004

10) Klareskog L, van der Heijde D, de Jager JP, et al:Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis:double-blind randomised controlled trial. Lancet 363:675-681, 2004

11) Nishimoto N, Hashimoto J, Miyasaka N, et al:Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI):evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66:1162-1167, 2007

12) Rachner TD, Khosla S, Hofbauer LC:Osteoporosis:now and the future. Lancet 377:1276-1287, 2011

13) Redlich K, Hayer S, Maier A, et al:Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 46:785-792, 2002

14) Sato K, Suematsu A, Okamoto K, et al:Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203:2673-2682, 2006

15) Schurigt U, Hummel KM, Petrow PK, et al:Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice. Arthritis Rheum 58:422-434, 2008

16) Smolen JS, Han C, Bala M, et al:Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement:a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 52:1020-1030, 2005

17) Takayanagi H, Iizuka H, Juji T, et al:Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43:259-269, 2000

18) van der Heijde D, Klareskog L, Landewe【´】 R, et al:Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 56:3928-3939, 2007

19) van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al:Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis:two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54:1063-1074, 2006